Rahul Banerjee, MD, FACP (@rahulbanerjeemd@med-mastodon.com)
1 Post, 4 Following, 2 Followers · Assistant Professor at the University of Washington / Fred Hutchinson Cancer Center (Seattle, WA). #MMsm myeloma and CAR-T therapy.
Related Articles
Our Journey | Emily Whitehead Foundation
Emily Whitehead has been in remission since 2012 after receiving CAR T-cell therapy to treat her leukemia.
Physician perceptions regarding carfilzomib dosing in multiple myeloma
This value you provided is not a number. Please try again. This value you provided is not an integer. Please try again. The value enter…
ASTCT Committee on Practice Guidelines Survey on Evaluation & Management of Relapsed Refractory Multiple Myeloma after Failure of Chimeric Antigen Receptor T-Cell Therapy
Chimeric antigen receptor T-cell therapy (CAR-T) has revolutionized the management of relapsed and/or refractory multiple myeloma (RRMM). However, CAR-T treatment failure is not uncommon and…
FDA’s ODAC Rules Unanimously on a Faster Way to Approve Multiple Myeloma Therapies – Florida Hospital News and Healthcare Report
“Today’s unanimous ODAC vote – 12-0 in favor – is a milestone for the field of multiple myeloma,” said Dr. C. Ola Landgren, director of…
Sleep disturbance in cancer patients referred to an ambulatory integrative oncology consultation – PubMed
Although 64% of patients seeking IO consultation reported clinically significant SD, only 11% were seeking integrative approaches for managing SD. ESAS fatigue, hot flashes, well-being,…
XII International Conference “Complex treatment of plasma cell dyscrasias in 2024” – WELCOME ADDRESS
By using this website, you consent to us using cookies as described in this policy
Like a bridge over troubled water: keeping the myeloma down en route to CAR-T
Blood Cancer Journal – Like a bridge over troubled water: keeping the myeloma down en route to CAR-T
As FDA weighs another myeloma endpoint for accelerated approvals, experts say timely access is at stake
About 15 years ago, Carl Ola Landgren, M.D. Ph.D., noticed an encouraging yet potentially concerning trend in the treatment of multiple myeloma. | At an…
Definers and drivers of functional high-risk multiple myeloma: insights from genomic, transcriptomic, and immune profiling
Traditional prognostic models for newly diagnosed patients with multiple myeloma (MM), including International Staging System criteria and number of high-risk chromosomal abnormalities, are based on…
If They RECUR, You Should Refer: A Community Oncologist Patient ID Roundtable Summary
Chimeric antigen receptor-modified T cell (CAR-T) therapy has become a critical part of the armamentarium for the treatment of relapsed/refractory hematologic malignancies. As our experience…